

# Ferdinando Riccardi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3761207/publications.pdf>

Version: 2024-02-01

8  
papers

182  
citations

1937685

4  
h-index

1872680

6  
g-index

8  
all docs

8  
docs citations

8  
times ranked

308  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	1.3	23
2	A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale. <i>Future Oncology</i> , 2022, 18, 771-779.	2.4	3
3	Oncological Assistance in the Emergency Room Setting: The Role of a Dedicated Oncology Unit. <i>International Journal of Cancer Management</i> , 2021, 14, .	0.4	0
4	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	3.2	6
5	Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1281-1287.	1.6	126
6	Acceptance and Adherence of Oral Endocrine Therapy in Women with Metastatic Breast Cancer: Exacampania Group Study. <i>Breast Journal</i> , 2015, 21, 326-328.	1.0	7
7	Italian Multicenter Phase III Randomized Study of Cisplatin Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial. <i>Clinical Lung Cancer</i> , 2015, 16, 67-70.	2.6	17
8	Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey. <i>Future Oncology</i> , 2014, 10, 69-78.	2.4	0